Geneva Business School®
*Real Business. Responsible Leaders.*

MBA in Biotech Management. Business Case Study.

# Lonza: biotech manufacturing in a shifting landscape

## Background

Lonza Group, a Swiss multinational and a leading Contract Development and Manufacturing Organization (CDMO), plays a pivotal role in the biopharmaceutical sector. Known for its innovations in biologics and small molecules, Lonza's strategic expansion into emerging modalities like mRNA production highlights its capacity to adapt to market dynamics. This case study explores Lonza's strategies, challenges, and lessons for future biotech managers.

Lonza has consistently invested in advanced manufacturing capabilities, becoming a partner of choice for pharmaceutical companies. Its role as a CDMO means it manages everything from drug discovery to commercial-scale manufacturing. This is crucial as the biopharma industry sees rising demand for complex therapies like cell and gene therapies, vaccines, and mRNA-based treatments. However, the industry faces challenges like a volatile funding landscape and post-COVID-19 demand shifts, which Lonza has navigated by focusing on innovation and operational efficiency.

**Lonza provides a wide range of services, including:**

- Commercial mammalian and microbial manufacturing
- Clinical development and manufacturing
- Cell and gene therapy capabilities
- Oral drug product development services

## Strategic Decisions

1. **Organizational Restructuring**: In 2019, Lonza combined its Pharma & Biotech and Consumer Health & Nutrition segments to leverage innovation programs and technology platforms across the nutrition-pharma spectrum
2. **Focus on Throughput**: Lonza shifted from optimizing utilization to optimizing throughput, recognizing that finished projects were more valuable than busy employees
3. **Strategic Partnerships**: Lonza has formed partnerships with various biotechnology companies, providing tailored development strategies and flexible manufacturing solutions
4. **Vertical Integration**: The company has invested in expanding its capabilities across the value chain, from early-stage development to commercial manufacturing

Geneva Business School®
*Real Business. Responsible Leaders.*

## Assignments

1. **SWOT Analysis**
   Conduct a comprehensive SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis of Lonza's position in the biopharmaceutical manufacturing industry. Focus on their investments in biologics, mRNA manufacturing, and operational efficiency. Use recent financial reports and industry analyses to support your points.

   **Deliverable:** A comprehensive SWOT analysis

2. **Competitive Landscape Review**
   Compare Lonza's strategies with those of other leading CDMOs (e.g., WuXi Biologics or Merck KGaA). Identify similarities and differences in their approaches to innovation, capacity management, and market positioning.

   **Deliverable:** A comparative chart or a 1-2 page analytical report.

3. **Ethical Implications of Expansion**
   Outline the ethical considerations (sustainability, workforce impact, and community relations) in business expansions Lonza should address while expanding manufacturing facilities, particularly in regions like California (Roche facility acquisition) and Switzerland

   **Deliverable**: A short essay (500 words) outlining potential ethical dilemmas and proposed solutions.

4. **Innovation Strategy Evaluation**
   Analyze Lonza's approach to innovation. How does the company balance incremental improvements with breakthrough innovations?

   **Deliverables:** Propose a framework for evaluating the success of Lonza's innovation initiatives.

## Available sources:

- Lonza's official website: https://www.lonza.com/
- Lonza's investor relations page: https://www.lonza.com/investor-relations
- Industry reports from sources like McKinsey & Company: https://www.mckinsey.com/industries/life-sciences/our-insights
- Bioprocess International on Lonza's growth and CAPEX investments: BioProcess International
- Lonza's mission impossible: Supplying the world with mRNA vaccines: Fern Fort
- Fierce Pharma's analysis of Lonza's rebound and industry positioning: Fierce Pharma
- Insights on Lonza's IVT platform for mRNA production: Lonza
- Lonza invests in a manufacturing facility: Fierce Pharma
- Annual reports: https://www.lonza.com/investor-relations/financial-reports
- Case studies on Lonza's partnerships: https://www.lonza.com/biologics/mammalian/shaped-around-you